Fazio S, et al. - Bococizumab was tested for LDL-C lowering efficacy, safety, and tolerability in primary hypercholesterolemia patients. For this purpose, two multiple-dose phase II studies were conducted that yielded findings demonstrating safety as well as efficacy of bococizumab in lowering LDL-C in hypercholesterolemic subjects on high doses of statin.